Alerts will be sent to your verified email
Verify EmailAUROPHARMA
Aurobindo Pharma
|
Alkem Laboratories
|
Abbott India
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
294.0 . | n/a | n/a |
Europe DMF Filings
|
2037.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
848.0 . | 178.0 . | n/a |
Number of ANDA's Approved By USFDA
|
702.0 . | 152.0 . | n/a |
R&D as a % of Total Sales
|
5.3 % | 4.3 % | 0.02 % |
Financials
|
|||
5 yr Average ROE
|
13.97 % | 17.42 % | 28.3 % |
5yr average Equity Multiplier
|
1.51 | 1.42 | 1.45 |
5yr Average Asset Turnover Ratio
|
0.71 | 0.89 | 1.15 |
5yr Avg Net Profit Margin
|
12.77 % | 13.9 % | 17.01 % |
Price to Book
|
2.36 | 5.62 | 17.28 |
P/E
|
20.37 | 30.45 | 47.36 |
5yr Avg Cash Conversion Cycle
|
-49.62 Days | -31.98 Days | -49.8 Days |
Inventory Days
|
59.48 Days | 55.32 Days | 47.03 Days |
Days Receivable
|
28.34 Days | 41.28 Days | 19.26 Days |
Days Payable
|
115.71 Days | 114.28 Days | 108.53 Days |
5yr Average Interest Coverage Ratio
|
43.78 | 24.2 | 83.18 |
5yr Avg ROCE
|
16.69 % | 22.93 % | 36.46 % |
5yr Avg Operating Profit Margin
|
19.28 % | 18.1 % | 21.84 % |
5 yr average Debt to Equity
|
0.21 | 0.21 | 0.0 |
5yr CAGR Net Profit
|
2.21 % | 9.76 % | 15.17 % |
5yr Average Return on Assets
|
9.18 % | 12.26 % | 19.59 % |
Shareholdings
|
|||
Promoter Holding
|
51.82 % | 55.66 % | 74.99 % |
Share Pledged by Promoters
|
20.39 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.01 % | -3.18 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
9.25 % | 6.99 % | 4.05 % |
Aurobindo Pharma
|
Alkem Laboratories
|
Abbott India
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|